Few sectors have absorbed the twin shocks of a blockbuster new drug class and rapid advances in artificial intelligence quite like the pharmaceutical industry, and few companies sit closer to the centre of that story than AstraZeneca. In a recent interview with The Australian, the drugmaker’s chief financial officer set out how the Anglo-Swedish giant is positioning itself for the surge in demand for GLP-1 weight-loss and diabetes medicines, and how it is folding AI into the long, expensive business of discovering new treatments.
The conversation matters well beyond the company’s balance sheet. AstraZeneca is one of the largest pharmaceutical employers in Australia, with a substantial manufacturing operation at Macquarie Park in Sydney’s north that exports to markets across the region. Decisions made in the company’s boardroom about where to invest, which therapeutic areas to chase and how quickly to adopt new technology ripple through local jobs, clinical trials and the medicines Australians eventually find on the Pharmaceutical Benefits Scheme.
The GLP-1 gold rush
The GLP-1 class, the family of drugs behind Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, has become the most closely watched corner of the global drug market. Originally developed for type 2 diabetes, the medicines have proven strikingly effective at driving weight loss, and analysts now talk about the category swelling into a market worth well over US$100 billion a year by the early 2030s. That gravitational pull has drawn in almost every large drugmaker, AstraZeneca included, each hunting for a differentiated foothold in a field currently dominated by two players.
AstraZeneca’s approach has leaned towards oral formulations and combination therapies rather than trying to beat the incumbents at the injectable game they invented. The company has an oral GLP-1 candidate in its pipeline, licensed from a Chinese biotech, and has been assembling a broader cardiometabolic portfolio that aims to treat obesity as one part of a cluster of related conditions rather than as a standalone number on the scales. The financial logic is straightforward enough: a pill that patients can take at home, if it works and can be manufactured at scale, removes some of the supply and cost barriers that have dogged the injectable market and could widen the pool of people willing to start and stay on treatment.
Not everyone is convinced the economics are as clean as the headline market forecasts suggest. Sceptics point to the ferocious pricing pressure building in the category, the manufacturing capacity that Novo and Lilly have already locked in, and the real possibility that governments and insurers baulk at funding weight-loss drugs for tens of millions of otherwise healthy people. Being a fast follower in a two-horse race is a harder commercial proposition than being first, and AstraZeneca will need clear clinical differentiation to justify the spend. The company’s counter-argument is that the obesity market is large enough to support several winners, and that combination and oral products will carve out segments the pioneers have not fully served.
AI moves from hype to plumbing
On artificial intelligence, the tone from big pharma has shifted over the past two years from breathless promise to something more grounded. The industry has learned that AI is unlikely to conjure a finished drug out of thin air, but it is already proving genuinely useful in the grind of early research: sifting through vast libraries of molecules, predicting how proteins fold and interact, flagging which compounds are worth synthesising in a lab and which experiments to run next. AstraZeneca has built out its own data science capability and struck partnerships with technology firms to embed these tools across discovery and development.
The pitch to investors is about time and money. Bringing a new medicine to market can take more than a decade and cost billions of dollars, with the overwhelming majority of candidates failing somewhere along the way. If AI can trim even a fraction off that timeline or lift the success rate of clinical trials by pointing researchers towards the right targets and the right patients, the return is enormous. The more cautious view, shared by plenty inside the industry, is that these gains are real but incremental, and that the hardest and most expensive stage, the large human trials that actually prove a drug is safe and effective, remains stubbornly resistant to being sped up by software.
What it means for Australia
For Australia, both threads carry direct consequences. The country’s obesity and type 2 diabetes rates are high and rising, and demand for GLP-1 medicines has already outstripped supply at various points, leaving some diabetes patients scrambling as the drugs were snapped up for weight management. A credible third or fourth entrant in the category, particularly an oral option, could ease those shortages and eventually strengthen the case for broader PBS listing, a decision that turns on cost-effectiveness assessments by the Pharmaceutical Benefits Advisory Committee. Cheaper, easier-to-take medicines change that calculus.
The AI angle intersects with Australia’s ambitions in medical research and clinical trials. The nation has long punched above its weight in early-phase trials thanks to its research hospitals, well-regulated environment and diverse patient populations, and AstraZeneca runs a meaningful slice of its Australian activity through that ecosystem. As drug discovery becomes more data-driven, the question for local research institutions and the wider sector is whether Australia can supply the talent, the computing infrastructure and the health data governance needed to stay part of the global pipeline rather than becoming a passive importer of finished products. Sovereign capability in health data and AI has become a recurring theme in Canberra’s technology policy conversations, and pharma is squarely inside that debate.
There is also a strategic footnote worth noting for Australian readers. AstraZeneca’s chief executive, Pascal Soriot, famously ran the company from Sydney’s northern beaches for stretches of the pandemic, a reminder that a firm of this scale can be steered from almost anywhere and that its investment choices are made globally. The finance chief steering the numbers, Aradhana Sarin, has spoken about disciplined capital allocation as the company balances the cost of chasing GLP-1s, funding AI infrastructure and defending its established oncology and respiratory franchises. Where Australia lands in that allocation depends on the competitiveness of the local operating environment as much as on any single drug.
What’s next
The near-term markers to watch are clinical readouts from AstraZeneca’s oral GLP-1 and cardiometabolic programs, which will show whether the company’s differentiated bet holds up against the incumbents, and the evidence, still emerging, on whether its AI investments are translating into faster or more successful trials. For Australia, the practical questions are supply stability for existing patients, the eventual reimbursement pathway for new weight-loss options, and whether the country keeps a seat at the table as drug development is rewired around data. None of these will resolve quickly, but the direction of travel set out by the company’s finance chief points to a business betting heavily on both the pill and the algorithm.
Sources: The Australian.
